...
首页> 外文期刊>Life sciences >Role of 5-HT1B/1D receptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats
【24h】

Role of 5-HT1B/1D receptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats

机译:5-HT1B / 1D受体在减少由偏头痛药物引起的福尔马林诱导的伤害感受和继发性痛觉过敏/痛觉过敏中的作用

获取原文
获取原文并翻译 | 示例

摘要

Aims The present study analyzed the potential antinociceptive effect of the antimigraine drugs sumatriptan, dihydroergotamine or methysergide in rats submitted to the formalin test. Moreover, by using selective antagonists, the role of 5-HT1B/1D serotonergic receptors was investigated in the antinociception induced by these antimigraine drugs. Main methods The formalin test was used to assess the nociceptive activity. Overt pain-like behavior (flinching, 1 h) and evoked nociception (long-lasting secondary mechanical allodynia and hyperalgesia, 6 days) were determined in the same rat. Key findings Ipsilateral, but not contralateral, pre-treatment (in μg/paw) with sumatriptan (10-300), methysergide (1-30) or dihydroergotamine (1-30) significantly prevented flinching behavior (at 1 h) as well as secondary allodynia and hyperalgesia (at day 6) induced by formalin. Interestingly, the antinociceptive (flinching), antiallodynic and antihyperalgesic effects of sumatriptan were completely prevented by peripheral pre-treatment with selective antagonists at the 5-HT1B (SB 224289; 100) or 5-HT1D (BRL 15572; 100) receptors. In contrast, the acute antinociceptive effects of methysergide and dihydroergotamine were partially prevented by SB 224289 and BRL 15572. The antiallodynic and antihyperalgesic effects of both drugs were completely prevented by BRL 15572 and partially prevented by SB 224289. Given alone, SB 224289 or BRL 15572 did not modify per se the long-lasting secondary allodynia and hyperalgesia. Significance The above findings suggest that: (i) the antimigraine drugs sumatriptan, methysergide and dihydroergotamine reduce the acute and chronic nociception induced by formalin; and (ii) this antinociceptive effect results from activation of peripheral 5-HT 1B/1D serotonergic receptors.
机译:目的本研究分析了抗偏头痛药物舒马曲坦,二氢麦角胺或美塞麦肽在福尔马林试验中的潜在镇痛作用。此外,通过使用选择性拮抗剂,研究了5-HT1B / 1D血清素能受体在这些抗偏头痛药物诱导的抗伤害感受中的作用。主要方法福尔马林测试用于评估伤害感受活性。在同一只大鼠中确定了明显的疼痛样行为(畏缩,1 h)和诱发的伤害感受(持久的继发性机械性异常性疼痛和痛觉过敏,6天)。主要研究结果:使用舒马普坦(10-300),美塞麦肽(1-30)或二氢麦角胺(1-30)进行同侧而非对侧预处理(以微克/爪为单位)可以显着预防退缩行为(在1 h时)以及福尔马林引起的继发性异常性疼痛和痛觉过敏(第6天)。有趣的是,通过在5-HT1B(SB 224289; 100)或5-HT1D(BRL 15572; 100)受体上进行选择性拮抗剂的外周预处理,可完全预防舒马曲坦的镇痛(退缩),抗痛觉过敏和抗痛觉过敏作用。相比之下,SB 224289和BRL 15572可以部分阻止甲基异麦角胺和二氢麦角胺的急性镇痛作用。BRL15572可以完全阻止两种药物的抗痛觉过敏和抗痛觉过敏作用,SB 224289可以完全阻止两种药物的止痛和抗痛觉过敏作用。单独使用SB 224289或BRL 15572本身并没有改变持久的继发性异常性疼痛和痛觉过敏。意义上述发现表明:(i)抗偏头痛药物舒马普坦,美塞麦肽和二氢麦角胺可减轻福尔马林引起的急性和慢性伤害感受; (ii)这种抗伤害感受作用是由外周5-HT 1B / 1D血清素能受体的激活引起的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号